What are the challenges with multi-targeted drug design for complex diseases?

Expert Opin Drug Discov. 2022 Jul;17(7):673-683. doi: 10.1080/17460441.2022.2072827. Epub 2022 May 12.

Abstract

Introduction: Current findings on multifactorial diseases with a complex pathomechanism confirm that multi-target drugs are more efficient ways in treating them as opposed to single-target drugs. However, to design multi-target ligands, a number of factors and challenges must be taken into account.

Areas covered: In this perspective, we summarize the concept of application of multi-target drugs for the treatment of complex diseases such as neurodegenerative diseases, schizophrenia, diabetes, and cancer. We discuss the aspects of target selection for multifunctional ligands and the application of in silico methods in their design and optimization. Furthermore, we highlight other challenges such as balancing affinities to different targets and drug-likeness of obtained compounds. Finally, we present success stories in the design of multi-target ligands for the treatment of common complex diseases.

Expert opinion: Despite numerous challenges resulting from the design of multi-target ligands, these efforts are worth making. Appropriate target selection, activity balancing, and ligand drug-likeness belong to key aspects in the design of ligands acting on multiple targets. It should be emphasized that in silico methods, in particular inverse docking, pharmacophore modeling, machine learning methods and approaches derived from network pharmacology are valuable tools for the design of multi-target drugs.

Keywords: Drug design; multi-target drugs; multifactorial diseases; polypharmacology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Design
  • Humans
  • Ligands
  • Neurodegenerative Diseases* / drug therapy
  • Schizophrenia* / drug therapy

Substances

  • Ligands